

MALIGNANT HYPERTHERMIA TREATMENT WITH AGILUS

(dantrolene sodium hemiheptahydrate)¹

In combination with adequate support measures, AGILUS® is indicated for the treatment of malignant hyperthermia in adults and children of all ages.¹



AGILUS® should be administered rapidly by intravenous injection at a **dose of 2.5 mg/kg body weight** for both adult and paediatric patients.¹



1

Calculate

the number of vials of AGILUS® required (see table below). Each vial contains 120 mg of dantrolene.



2

Reconstitute

each vial with 20 mL of water for injections and shake for approximately 1 minute, before inspecting for particulates. Further shaking may be necessary.



3

Administer

reconstituted AGILUS® without mixing with other solutions or giving via the same venous access.



4

Apply

other supportive measures alongside AGILUS®.

Dosing examples by body weight to achieve a dose of 2.5 mg/kg for both adults and children¹

For all body weights ≥ 120 kg, the maximum amount given as a single bolus for each individual dose (whether an initial or repeat dose) should not exceed 300 mg.

Number of vials to be prepared	Body weight range	Example dosing recommendation	
		Body weight	Dose to be administered
1	Up to 48 kg	3 kg	7.5 mg
		6 kg	15 mg
		12 kg	30 mg
		24 kg	60 mg
		48 kg	120 mg
2	From 49 kg to 96 kg	72 kg	180 mg
		96 kg	240 mg
3	From 97 kg	120 kg	300 mg
		144 kg	300 mg

Please refer to the Summary of Product Characteristics for full dosing details.



As long as the main clinical symptoms persist, a bolus injection of 2.5 mg/kg should be repeated every **10 minutes** until physiological and metabolic abnormalities improve.¹ If a cumulative dose of 10 mg/kg or above is considered, the diagnosis of malignant hyperthermia should be re-examined.¹

Click or scan to view Prescribing Information

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Norgine Pharmaceuticals Ltd on: Tel: +44 (0)1895 826 606 Email: medinfo@norgine.com



Note: AGILUS® is a skeletal muscle relaxant. The most commonly reported adverse event is skeletal muscle weakness.

1. AGILUS®, Summary of Product Characteristics.

Job code: UK-EC-AGI-2500017 Date of preparation: October 2025